HP Inc vs BIO-TECHNE Corp — how do they compare? HP Inc trades at $24.6 (market cap $22.15B), while BIO-TECHNE Corp trades at $71.72 (market cap $11.16B). The key difference: HP Inc is the larger of the two by market cap, and HP Inc pays the higher dividend (4.95%). Which is the better fit depends on your goals.
| HPQ | TECH | |
|---|---|---|
Market Cap | $22.15B | $11.16B |
Sector | Technology | Health |
52-Week High | $29.35 | $72.12 |
52-Week Low | $18.20 | $43.31 |
Enterprise Value | $29.31B | $11.24B |
Dividend Yield | 4.95% | 0.45% |
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $24.395, down 1.79% on the day, with a bullish technical setup showing strong moving average signals. The stock offers attractive valuation metrics including a P/E of 9.2 and P/S of 0.41, with consistent earnings beats in recent quarters. Recent developments include strategic partnerships with OpenAI and Ferrari, positioning the company for AI PC growth. Cash flow trends show improvement with 2025 net cash flow of $460 million, though revenue has declined from 2022's $63B to $55.3B in 2025.
HPQ presents a value opportunity with strong dividend yield and improving cash flows, but faces headwinds from PC market volatility and competitive pressures. Analyst sentiment is mixed with 29% buy ratings versus 55% hold, suggesting cautious optimism. The stock's near-term performance will depend on AI PC adoption and execution of new strategic partnerships.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Trailing returns across standard periods
Latest headlines on both assets
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →